CL2016002569A1 - Anticuerpos, composiciones farmacéuticas y usos de los mismos - Google Patents

Anticuerpos, composiciones farmacéuticas y usos de los mismos

Info

Publication number
CL2016002569A1
CL2016002569A1 CL2016002569A CL2016002569A CL2016002569A1 CL 2016002569 A1 CL2016002569 A1 CL 2016002569A1 CL 2016002569 A CL2016002569 A CL 2016002569A CL 2016002569 A CL2016002569 A CL 2016002569A CL 2016002569 A1 CL2016002569 A1 CL 2016002569A1
Authority
CL
Chile
Prior art keywords
antibodies
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
CL2016002569A
Other languages
English (en)
Inventor
Cheng-Chi Wang
Cheng-Der Tony Yu
I-Ju Chen
Jiann-Shiun Lai
Yi-Chien Tsai
Original Assignee
Obi Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obi Pharma Inc filed Critical Obi Pharma Inc
Publication of CL2016002569A1 publication Critical patent/CL2016002569A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation
CL2016002569A 2014-04-10 2016-10-07 Anticuerpos, composiciones farmacéuticas y usos de los mismos CL2016002569A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461977824P 2014-04-10 2014-04-10
US201462057381P 2014-09-30 2014-09-30

Publications (1)

Publication Number Publication Date
CL2016002569A1 true CL2016002569A1 (es) 2017-09-08

Family

ID=54288553

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002569A CL2016002569A1 (es) 2014-04-10 2016-10-07 Anticuerpos, composiciones farmacéuticas y usos de los mismos

Country Status (17)

Country Link
US (2) US9902779B2 (es)
EP (2) EP3129048B1 (es)
JP (1) JP2017512759A (es)
KR (1) KR101966408B1 (es)
CN (2) CN112390887B (es)
AU (2) AU2015243246B2 (es)
BR (1) BR112016020009A2 (es)
CA (2) CA2941029C (es)
CL (1) CL2016002569A1 (es)
ES (1) ES2772817T3 (es)
IL (2) IL246837B (es)
PH (1) PH12016501976A1 (es)
RU (1) RU2016138744A (es)
SG (1) SG11201607258SA (es)
TW (3) TWI609886B (es)
WO (1) WO2015157629A2 (es)
ZA (1) ZA201605175B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015143123A2 (en) 2014-03-19 2015-09-24 Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
AU2015243246B2 (en) 2014-04-10 2018-09-06 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
JP2018532990A (ja) 2015-09-04 2018-11-08 オービーアイ ファーマ，インコーポレイテッド グリカンアレイおよび使用の方法
US10501532B2 (en) * 2015-10-07 2019-12-10 Obi Pharma, Inc. Carbohydrate antibodies, pharmaceutical compositions and uses thereof
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
TWI780045B (zh) 2016-03-29 2022-10-11 台灣浩鼎生技股份有限公司 抗體、醫藥組合物及方法
CN109379889A (zh) 2016-04-22 2019-02-22 台湾浩鼎生技股份有限公司 通过经由globo系列抗原的免疫激活或免疫调节的癌症免疫疗法
GB201612317D0 (en) * 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
BR112019001656A2 (pt) 2016-07-27 2019-05-28 Obi Pharma Inc composição, composição farmacêutica, vacina, método para induzir anticorpos em um indivíduo, método para tratar câncer em um paciente necessitando do mesmo e método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo
CN110062767B (zh) 2016-07-29 2023-07-11 台湾浩鼎生技股份有限公司 人抗体、药物组合物和方法
CN110290800A (zh) * 2016-11-21 2019-09-27 台湾浩鼎生技股份有限公司 缀合生物分子、医药组合物及方法
TWI714854B (zh) * 2017-05-24 2021-01-01 財團法人生物技術開發中心 抗globo h之人類化抗體及其於治療癌症之用途
CA3093838A1 (en) * 2018-03-14 2019-09-19 Memorial Sloan Kettering Cancer Center Anti-polysialic acid antibodies and uses thereof
WO2019232519A1 (en) * 2018-06-01 2019-12-05 Obi Pharma, Inc. Combination therapy by using anti-globo h or anti-ssea-4 antibody with anti-negative immune check points antibody
WO2020006176A1 (en) 2018-06-27 2020-01-02 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
KR20220016044A (ko) * 2019-03-28 2022-02-08 밍-테인 라이 글로보-h 관련 암 치료법을 위한 동반 진단 검정
WO2022173772A1 (en) * 2021-02-09 2022-08-18 Obi Pharma, Inc. Globo series antigens-binding chimeric antigen receptors and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
WO2001071005A2 (en) 2000-03-24 2001-09-27 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
DE60124912T2 (de) * 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
BR0107262B1 (pt) 2001-12-17 2014-04-22 Da Fonseca Clovis Orlando Pereira Composição farmacêutica inalatória
US20040126829A1 (en) 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
EP1505075B1 (en) 2002-04-30 2009-10-07 Kyowa Hakko Kirin Co., Ltd. Antibody to human insulin-like growth factor
DE60334453D1 (de) * 2002-05-30 2010-11-18 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
AT413486B (de) * 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
EP1766093B1 (en) 2004-02-06 2011-06-15 University of Massachusetts Antibodies against clostridium difficile toxins and uses thereof
EP1791868B1 (en) * 2004-07-01 2011-02-23 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
KR100958505B1 (ko) 2004-07-18 2010-05-17 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제
WO2006134423A2 (en) 2004-07-18 2006-12-21 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
EP2284194A1 (en) * 2004-12-21 2011-02-16 AstraZeneca AB Antibodies directed to angiopoietin-2 and uses thereof
EP2402374A1 (en) * 2005-02-07 2012-01-04 GlycArt Biotechnology AG Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
ES2432091T5 (es) * 2005-03-25 2022-03-18 Gitr Inc Moléculas de unión GITR y usos de las mismas
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
US20100145032A1 (en) * 2007-01-18 2010-06-10 Suomen Punainen Risti, Veripalelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
MX2010013931A (es) 2008-06-16 2011-06-01 Academia Sinica Diagnosis de cancer basada en niveles de anticuerpos contra globo h y sus fragmentos.
JP2011524375A (ja) * 2008-06-16 2011-09-01 アカデミア シニカ ＧｌｏｂｏＨおよびＳＳＥＡ３に特異的な免疫反応を誘起する組成物および癌治療におけるその使用
TWI583393B (zh) * 2009-06-16 2017-05-21 中央研究院 免疫原性組合物、包含其之疫苗與治療劑及其用途
DK2462161T3 (en) * 2009-08-06 2017-06-06 Immunas Pharma Inc Antibodies specifically binding to A-beta oligomers and their use
BR112012025730B1 (pt) * 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
EA201300074A1 (ru) * 2010-07-01 2013-06-28 ДСМ АйПи АССЕТС Б.В. Способ получения представляющего интерес соединения
EP2606066A1 (en) * 2010-08-16 2013-06-26 Amgen Inc. Antibodies that bind myostatin, compositions and methods
TW201307388A (zh) * 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
EP2497782A1 (en) * 2011-03-08 2012-09-12 Alzinova AB Anti oligomer antibodies and uses thereof
WO2013052745A1 (en) 2011-10-06 2013-04-11 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-erbb3 antibodies
EP3093293A1 (en) 2012-02-24 2016-11-16 Stemcentrx, Inc. Anti dll3 antibodies and methods of use thereof
AU2015206370A1 (en) 2014-01-16 2016-07-07 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015143123A2 (en) * 2014-03-19 2015-09-24 Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
AU2015243246B2 (en) 2014-04-10 2018-09-06 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
RU2016138744A3 (es) 2018-05-11
TW201738277A (zh) 2017-11-01
AU2018253589A1 (en) 2018-11-22
KR101966408B1 (ko) 2019-04-05
IL276695B (en) 2021-09-30
IL246837B (en) 2020-08-31
TW201546092A (zh) 2015-12-16
CA2941029A1 (en) 2015-10-15
EP3129048A4 (en) 2017-10-25
US20180134799A1 (en) 2018-05-17
WO2015157629A2 (en) 2015-10-15
TW201738276A (zh) 2017-11-01
IL276695A (en) 2020-09-30
US9902779B2 (en) 2018-02-27
AU2015243246A1 (en) 2016-09-08
KR20160137984A (ko) 2016-12-02
TWI697503B (zh) 2020-07-01
EP3662928A1 (en) 2020-06-10
EP3129048A2 (en) 2017-02-15
ES2772817T3 (es) 2020-07-08
TWI695013B (zh) 2020-06-01
US10815307B2 (en) 2020-10-27
SG11201607258SA (en) 2016-10-28
PH12016501976A1 (en) 2016-12-19
AU2018253589B2 (en) 2020-04-16
CN106456727B (zh) 2020-11-27
JP2017512759A (ja) 2017-05-25
WO2015157629A3 (en) 2015-12-03
BR112016020009A2 (pt) 2017-10-17
EP3129048B1 (en) 2020-01-15
CA2941029C (en) 2021-02-16
CN112390887A (zh) 2021-02-23
TWI609886B (zh) 2018-01-01
ZA201605175B (en) 2017-09-27
CN112390887B (zh) 2023-09-26
CN106456727A (zh) 2017-02-22
CA3104268A1 (en) 2015-10-15
IL246837A0 (en) 2016-08-31
AU2015243246B2 (en) 2018-09-06
US20170029526A1 (en) 2017-02-02
RU2016138744A (ru) 2018-05-11

Similar Documents

Publication Publication Date Title
CL2016002569A1 (es) Anticuerpos, composiciones farmacéuticas y usos de los mismos
CL2016002252A1 (es) Anticuerpos anti-egfrviii y usos de los mismos
CL2016002364A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparación y uso de las mismas
DK3529248T3 (da) Farmaceutiske sammensætninger
BR112016023628A2 (pt) composições farmacêuticas.
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
DK3466976T3 (da) Anti-her2-antistof-lægemiddelkonjugat
DK3297605T3 (da) Topiske, farmaceutiske sammesætninger
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
DK3229810T3 (da) Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
BR112016026879A2 (pt) Composição farmacêutica líquida
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
DK3532029T3 (da) Flydende farmaceutisk sammensætning
DK3199161T3 (da) Farmaceutisk præparat
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes
DK3463345T3 (da) Farmaceutiske kombinationer
DK3110837T3 (da) Tatk-cdkl5-fusionsproteiner, sammensætninger, formule-ringer og anvendelse deraf
DK3191085T3 (da) Misbrugsresistente farmaceutiske sammensætninger
DK3229843T3 (da) Farmaceutisk sammensætning, præparat og anvendelser deraf
CL2017002226A1 (es) Etv2 y usos de los mismos
BR112016027383A2 (pt) Derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação
DK3280447T3 (da) Farmaceutiske formuleringer
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
DK3288967T3 (da) Farmaceutisk forbindelse